SABCS 2017: Eribulin mesylate and pembrolizumab in patients with metastatic triple-negative breast cancer

Eisai today announced updated results of ENHANCE 1, a Phase 1b/2 trial investigating eribulin mesylate, in combination with pembrolizumab, in patients with metastatic triple-negative breast cancer . Findings presented during the 2017 San Antonio Breast...

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2AswkGZ
via IFTTT